<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87537">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02142751</url>
  </required_header>
  <id_info>
    <org_study_id>FOREST</org_study_id>
    <nct_id>NCT02142751</nct_id>
  </id_info>
  <brief_title>Fosfomycin Versus Meropenem in Bacteriemic Infections Caused by ESBL-E. Coli</brief_title>
  <acronym>FOREST</acronym>
  <official_title>Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem in the Treatment of Bacteriemic Urinary Infection Due to Extended-Spectrum βeta-lactamase (ESBL) Escherichia Coli</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Network for Research in Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enterobacterieaceae (and specially Escherichia coli) showing resistance due to
      extended-spectrum β-lactamases (ESBLs) have spread worldwide during the last decades. This
      is important because many of these isolates are also resistant to other first-line agents
      such as fluoroquinolones or aminoglycosides, leaving few available options for therapy, and
      this condition is associated with increased morbidity- mortality and length of hospital
      stay. While carbapenems are considered the drugs of choice for ESBL and AmpC producers,
      recent data suggests that certain alternatives may be suitable for some types of infections.

      At the present time, finding therapeutic alternatives to carbapenems for the treatment of
      invasive infections due to extended-spectrum beta-lactamase (ESBL) Escherichia coli
      (ESBL-Ec) is critical. Fosfomycin was discovered more than 40 years ago but was not
      investigated according to present standards, and thus is not used in clinical practice
      except in desperate situations. It is one of the so-considered neglected antibiotics with
      high potential interest for the future.

      With the aim of demonstrate the clinical non-inferiority of intravenous fosfomycin compared
      to meropenem in the treatment of bacteraemic urinary tract infections caused by ESBL-Ec. The
      investigators propose a &quot;real practise&quot; randomised, controlled, multicentre phase III
      clinical trial to compare the clinical and microbiological efficacy and safety of
      intravenous fosfomycin (4 grammes every 6 hours) with meropenem (1 gramme every 8 hours) as
      targeted therapy of the previously specified infection; change to oral therapy according to
      predefined options is allowed in both arms after 5 days. Follow-up for the study is planned
      up to 60 days.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical and microbiological cure rate</measure>
    <time_frame>Day 5-7 after end of treatment (test of cure)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Cure: Complete resolution of infection symptoms (bacteremia and/or urinary tract infection-UTI-), present at the day on which blood culture was drawn.
Microbiological cure: Negative blood culture at day 5-7 after end of treatment. Besides this, if UTI was confirmed with a positive urine culture with the same microorganism than the blood culture, this culture should become negative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early clinical response</measure>
    <time_frame>After 5 days of complete treatment (from the first day of study drugs administration)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The infection was completely resolved after 5 days of complete treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>At day 30 of follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Death for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>At day 30 of follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>It is defined as the time from admission to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of intravenous fosfomycin in this indication</measure>
    <time_frame>To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Gathering any related adverse event from the informed consent form signature to the end of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrences (relapse and reinfection) rate</measure>
    <time_frame>To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relapse: new symptoms of UTI in patient with previously considered as clinical or microbiological cured  in the visit of day 5-7 plus positive urine or blood cultures with the same microorganism isolated than the initial culture.
Re-infection: same definition but with different strain in the culture results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fosfomycin steady-state plasma concentration</measure>
    <time_frame>At 3 days after treatment started</time_frame>
    <safety_issue>No</safety_issue>
    <description>Therapeutic drug monitoring of fosfomycin, basic pharmacokinetic parameters will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota impact of study treatment bacilli</measure>
    <time_frame>Screening, day 5-7, day 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Study treatment impact in the gut colonization of MDRGNB (Multi drug resistant Gram negative bacilli)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of resistant clinical isolates of Escherichia coli to fosfomycin and meropenem</measure>
    <time_frame>participants will be followed for the duration of fosfomicin, an expected average of 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency of strains that develop resistance and detection of resistance mechanisms in fosfomycin treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early microbiological response</measure>
    <time_frame>within the first 5 days after treatment started</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cultures are negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of intravenous antibiotic administration in this indication</measure>
    <time_frame>To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Gathering any related adverse event from the informed consent form signature to the end of follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Infection Due to ESBL Escherichia Coli</condition>
  <arm_group>
    <arm_group_label>Fosfomycin sodium intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4g every 6 hours iv (60 min infusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1g every 8 hours (15-30 min infusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosfomycin sodium intravenous</intervention_name>
    <description>4g every 6 hours iv (60 min infusion)</description>
    <arm_group_label>Fosfomycin sodium intravenous</arm_group_label>
    <other_name>Generic name: Fosfomycin</other_name>
    <other_name>Pharmaceutical form: solution for infusion</other_name>
    <other_name>ATC code: J01J3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem intravenous</intervention_name>
    <description>1g every 8 hours (15-30 min infusion)</description>
    <arm_group_label>Meropenem intravenous</arm_group_label>
    <other_name>Generic name: Meropenem</other_name>
    <other_name>Pharmaceutical form: solution for infusion</other_name>
    <other_name>ATC code: J01D5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years old hospitalized patients

          -  Negative pregnancy test in fertile women

          -  Episode of clinically-significant monomicrobial urinary BSI due to ESBL- E.coli
             susceptible to fosfomycin and meropenem

          -  Urinary sepsis with ESBL- E. coli isolation from the blood cultures, requires at
             least one clinical criteria and one of the following urinalysis criteria:

        Clinical criteria

          -  UTI symptoms (dysuriac, urgency, suprapubic pain or pollakiuria)

          -  Lumbar back pain

          -  Cost-vertebral angle tenderness

          -  Altered mental status in people up to 70 years old

          -  Intermittent or permanent indwelling foley catheter (or withdrawal during 24 hours
             previous) even without urinary symptoms urinalysis criteria

          -  Urine dipstick test positive for either nitrites or leukocyte esterase

          -  Positive urine culture - Signed informed consent form (ICF) executed prior to
             protocol screening assessments

        Exclusion Criteria:

          -  Polymicrobial bacteremia

          -  No drainage of renal abscess or obstructive uropathy unresolved

          -  Pregnant or careening women

          -  Acute and chronic prostatitis

          -  Haematogenous infection

          -  Other concomitant infection

          -  Renal transplantation recipients

          -  Polycystic kidney

          -  Hypersensitivity and/or intolerance to meropenem or fosfomycin

          -  Palliative care or  life expectance &lt; 90 days

          -  Septic shock at time of randomization

          -  New York Heart Association (NYHA) functional Class III or IV, hepatic cirrhosis or
             renal impairment receiving dialysis

          -  Active empiric treatment &gt;72 hours

          -  Late randomization &gt;24 hours after ESBL-E.coli blood culture´s identification

          -  Participation in other clinical trial with active treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JESUS RODRIGUEZ-BAÑO, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Spanish Network for Research in Infectious Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara M. Rosso Fernández, MD, PhD</last_name>
    <phone>+34955013414</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angel Barriga, BD</last_name>
    <phone>+34955013414</phone>
    <email>angel.barriga.exts@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anna San Gil Betriu, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Las Palmas de Gran Canarias</city>
        <state>Gran Canarias</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Miguel Angel Cárdenas Santana, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Vilanova</city>
        <state>Lleida</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fernando Barcenilla Gaite, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alicia Hernández Torres, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>María Lecuona Fernández, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vicente Voix Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marina Baixa</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Concepción Amador Prous, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i San Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Virginia Pomar Solchaga, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carlos Pigrau Serrallach, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Evelyn Shaw Perujo, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Salud Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>María Luisa Sorli Redó, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carlos Dueñas Gutiérrez, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clara Natera, MD, PhD</last_name>
      <email>clrntr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Clara Natera, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vicente Pintado García, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>José Tiago Sequeira López da Silva, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ana María Fleites Gutiérrez, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nuria Borrel Solé, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecillas</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luis Martínez Martínez, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesús Sojo Dorado, MD</last_name>
      <phone>+34 955009024</phone>
      <email>jesodo@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Adoración Valiente</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jesús Sojo Dorado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zaira R Palacios Baena, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vicente Merino Bohorquez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adoración Valiente, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Miguel Salavert Lletí, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Royo Villanova</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rosa María Martínez Alvarez, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.reipi.org/</url>
    <description>Spanish Network Research in Infectious Diseases (Red Española de Investigación en Patología Infecciosa [REIPI])</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>May 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Escherichia coli</keyword>
  <keyword>Extended-spectrum β-lactamases (ESBLs)</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>Urinary tract infection</keyword>
  <keyword>Bloodstream infection</keyword>
  <keyword>Fosfomycin</keyword>
  <keyword>Meropenem</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>intestinal colonization</keyword>
  <keyword>Recurrence</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fosfomycin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
